<qa>  What is the purpose of this study?The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine FUDR and dexamethasone Dex regional chemotherapy, and either oxaliplatin or CPT-11, plus 5-fluorouracil and leucovorin systemic chemotherapy will increase disease free survival in patients who have undergone liver resection. The patient will be randomized a computer generated decision as in the flip of a coin to receive, or not to receive bevacizumab in addition to regional and systemic chemotherapy. 